Last quarter (Q ), Ascendis Pharma's total revenue was €―, a decrease of -100.00% from the same quarter last year. In Q, Ascendis Pharma's net income was €―. See Ascendis Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	€ 28.28M	€ 51.17M	€ 7.78M	€ 6.95M	€ 13.38M	€ 10.58M
Cost of Revenue	€ 7.03M	€ 12.14M	€ 3.52M	€ 0.00	-	-
Gross Profit	€ 21.25M	€ 39.04M	€ 4.25M	€ 6.95M	-	-
Operating Expense	€ 435.68M	€ 600.85M	€ 456.05M	€ 337.57M	€ 240.09M	€ 165.34M
Operating Income	€ -414.43M	€ -561.81M	€ -451.79M	€ -330.62M	€ -226.72M	€ -154.76M
Net Non Operating Interest Income Expense	€ 48.42M	€ 52.18M	€ -3.22M	€ -106.00K	€ 8.84M	€ 3.89M
Other Income Expense	€ -9.73M	€ 68.18M	€ 71.07M	€ -88.45M	€ -366.00K	€ 20.37M
Pretax Income	€ -375.75M	€ -577.82M	€ -383.94M	€ -419.17M	€ -218.25M	€ -130.49M
Tax Provision	€ 27.00K	€ 5.38M	€ -367.00K	€ -219.00K	€ -234.00K	€ -394.00K
Earnings From Equity Interest Net Of Tax	-	€ -17.70M	-	-	-	-
Net Income Common Stockholders	€ -375.77M	€ -583.19M	€ -383.58M	€ -418.95M	€ -218.02M	€ -130.10M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	€ 442.70M	€ 612.99M	€ 459.57M	€ 337.57M	€ 240.09M	€ 165.34M
Net Income From Continuing And Discontinued Operation	€ -375.77M	€ -583.19M	€ -383.58M	€ -418.95M	€ -218.02M	€ -130.10M
Normalized Income	€ -375.77M	-	€ -442.54M	€ -340.07M	€ -225.75M	€ -150.73M
Interest Expense	€ 56.08M	-	€ 3.91M	€ 1.92M	€ 1.22M	€ 127.00K
EBIT	€ -319.67M	€ -630.00M	€ -380.03M	€ -417.26M	€ -217.03M	€ -130.36M
EBITDA	€ -306.34M	€ -612.04M	€ -364.64M	€ -407.81M	€ -210.34M	€ -129.48M

Currency in EUR

Ascendis Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing